When a company such as Syros Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SYRS split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Syros Pharmaceuticals shares, starting with a $10,000 purchase of SYRS, presented on a split-history-adjusted basis factoring in the complete SYRS split history.

About Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients. According to our SYRS split history records, Syros Pharmaceuticals has had 1 split.

SYRS Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved